• Health and Nutrition

Blood-Brain Barrier Laboratory (LBHE)

Research unit - UR 2465


The Blood-Brain Barrier Laboratory (LBHE) develops and optimizes animal (bovine, rat, mouse) and human (stem cell or iPSCs) models of BHE to:
- study the physiology and integrity of the BBB and the intercommunications between cells of the central nervous system (CNS),
- to better understand the role of this barrier in neurodegenerative diseases and in the development of cancers or metastases within the CNS,
- to predict brain distribution and toxicity of new chemical and biological entities (antibodies, proteins, etc.),
- to develop new approaches or molecules in order to deliver therapeutic agents to the CNS (nanoparticles, etc.),
- identify the mechanisms of infection of the CNS by microorganisms (viruses, bacteria, etc.),
For more than 30 years, we have been working closely with many other academic teams but also with private sector companies (research services, CIFRE, research contracts, licenses, etc.). Our Mass Spectrometry (SMART) platform allows us to offer molecular analysis solutions to our various partners.


  • Fabien Gosselet


Rue Jean Souvraz
UFR des Sciences Perrin
62308 LENS


Blood-Brain Barrier Laboratory


Effectif total : 28

Personnel de recherche : 10

Personnel d'appui à la recherche : 8



• In vitro modelling of the blood-brain barrier (BBB) using animal models or a human model based on hematopoietic stem cells or iPSCs.
• Use these models to study cell intercommunications, predict the brain toxicity of molecules, or measure their velocity to the brain compartment.
• Role of blood-brain barrier in neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, etc.), influence of polluting, environmental, and dietary factors on BBB permeability and physiology.
• Dosage of molecules in buffer or physiological solutions.
• Proteomic studies of cell cultures.

Example(s) of projects

• Development of a human model to predict toxicity and passage of molecules to the brain: 🡭

• Miniaturization and optimization of this human model to fit high throughput screening (HTS): 🡭

• Development of a blood-tumour barrier model for glioblastoma vascular studies: 🡭

• Molecule interaction studies with efflux pumps expressed by physiological barriers: 🡭

• Demonstrated influence of diet on the physiology of BBB and in Alzheimer’s disease: 🡭

Example(s) of publications

• Miniaturization and Automation of a Human In Vitro Blood–Brain Barrier Model for the High-Throughput Screening of Compounds in the Early Stage of Drug Discovery.
Moya ELJ, Vandenhaute E, Rizzi E, Boucau M-C, Hachani J, Maubon N, Gosselet F, Dehouck M-P.
Pharmaceutics. 2021 Jun 16;13(6):892. 🡭

• Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound.
Wellens S, Dehouck L, Chandrasekaran V, Singh P, Loiola RA, Sevin E, Exner T, Paul J, Gosselet F, Culot M.
Toxicol In Vitro. 2021 Feb 22:105112. 🡭

• Contribution of brain pericytes in blood-brain barrier formation and maintenance: a transcriptomic study of cocultured human endothelial cells derived from hematopoietic stem cells.
Heymans M, Figueiredo R, Dehouck L, Francisco D, Sano Y, Shimizu F, Kanda T, Bruggmann R, Engelhardt B, Winter P, Gosselet F, Culot M.
Fluids Barriers CNS. 2020 Jul 28;17(1):48. 🡭

• Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C, Hachani J, Duban-Deweer S, Meignan S, Leblond P, Carcaboso AM, Sano Y, Shimizu F, Kanda T, Gosselet F, Dehouck MP, Mysiorek C.
Fluids Barriers CNS. 2020 Jun 2;17(1):37. 🡭

• GM1 Oligosaccharide Crosses the Human Blood-Brain Barrier In Vitro by a Paracellular Route.
Di Biase E, Lunghi G, Maggioni M, Fazzari M, Pomè DY, Loberto N, Ciampa MG, Fato P, Mauri L, Sevin E, Sonnino S, Chiricozzi E, Gosselet F
Int J Mol Sci. 2020 Apr 19;21(8):E2858. 🡭

• Secretome of endothelial progenitor cells from stroke patients promotes endothelial barrier tightness and protects against hypoxia-induced vascular leakage.
Loiola RA, García-Gabilondo M, Grayston A, Bugno P, Kowalska A, Duban-Deweer S, Rizzi E, Hachani J, Sano Y, Shimizu F, Kanda T, Mysiorek C, Mazurek MP, Rosell A, Gosselet F. Stem Cell Res Ther. 2021 Oct 26;12(1):552. doi: 10.1186/s13287-021-02608-y. PMID: 34702368. 🡭

Collaborations/Partners/Scientific clients

Numerous collaborations in the form of service contracts, research contracts, CIFRE grants, etc with many private partners of the pharmaceutical industry (confidential).

Services offers

Applications sectors

  • Science / Research

Services provided

• Predicting toxicity and measuring the speed of passage of molecules through the blood-brain barrier, interaction with efflux pumps (type P-gp, BCRP, etc.).
• Molecule assay or cell culture proteomic profile.

Training offers

Training in the culture of brain, glial and pericyte endothelial cells in order to reproduce in vitro the human blood-brain barrier, permeability calculations, functional tests of efflux pumps, extraction of mouse and oxen brain microvessels.

Consulting services

We provide consulting services on all our skills


Biological materials

Many types of primary and immortalized cells, human and animal to reproduce the blood-brain barrier in vitro.


Affiliated institutions / organisations


Doctoral schools

Competitive cluster

Regional strategic areas of activity

  • Health and Nutrition